5:12 PM
 | 
Mar 28, 2013
 |  BC Extra  |  Clinical News

Repros jumps on Phase III Androxal data

Repros Therapeutics Inc. (NASDAQ:RPRX) gained $6.97 (76%) to $16.10 on Thursday after once-daily oral Androxal enclomiphene met the...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >